Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.79 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 9/20 | 0.63 |
| ▸ | HTR2A | P28223 | 9/20 | 0.63 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6422114 | 0.99 | MAPKAPK2 (0.97) | MAPKAPK2SIRT1MAPKAPK5HTR2CHTR2A | |
| SCHEMBL6240174 | 0.85 | MAPKAPK2 (1.00) | MAPKAPK2SIRT1MAPKAPK5HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL6236292 | 0.84 | MAPKAPK2 (0.97) | MAPKAPK2MAPKAPK5HTR2CHTR2A | |
| SCHEMBL6238971 | 0.84 | MAPKAPK2 (0.74) | MAPKAPK2SIRT1MAPKAPK5HTR2CHTR2A | |
| SCHEMBL6240455 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2SIRT1MAPKAPK5HTR2CHTR2A | |
| SCHEMBL6239981 | 0.84 | MAPKAPK2 (0.74) | MAPKAPK2SIRT1MAPKAPK5HTR2CHTR2A | |
| SCHEMBL21723836 | 0.83 | MAPKAPK2 (0.71) | MAPKAPK2SIRT1HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL6360792 | 0.83 | MAPKAPK2 (0.73) | MAPKAPK2SIRT1MAPKAPK5HTR2CHTR2A | |
| SCHEMBL6241494 | 0.83 | MAPKAPK2 (0.83) | MAPKAPK2SIRT1MAPKAPK5 | |
| SCHEMBL23070186 | 0.82 | MAPKAPK2 (0.69) | MAPKAPK2SIRT1MAPKAPK5HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3836919-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | Recreo Pharmaceuticals Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| CN-112654354-A | 1,3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indole derivative compound and application thereof | 菲尼克思药业股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | MAPKAPK2 4867/4885SIRT1 1108/4885MAPKAPK5 4874/4885 |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885SIRT1 1037/4885MAPKAPK5 34/4885 |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 | MAPKAPK2 4797/4885SIRT1 1081/4885MAPKAPK5 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.